Are these Peptides for human use?

Products sold by Peptide Standard LLC™ are intended solely for laboratory research only. They are strictly prohibited from human or animal use, consumption, or administration.

How are quality standards maintained?

Every product we sell is independently tested by accredited third-party labs to confirm identity and purity. We screen all batches via HPLC & mass spectrometry to insure purity, product accuracy, and vial quantities. Downloadable, batch-specific COAs whether through our testing, or the manufacturers lab testing, are provided for every compound.

Do you ship internationally?

No. We currently only ship within the USA.

How should peptides be stored?

Store lyophilized peptides at -20°C away from light and moisture. Once reconstituted, refrigerate at 4°C and use according to your research timeline. Do not repeatedly freeze and thaw, as this can degrade the compound.

What type pf payments do you accept?

We accept all major credit cards via encrypted checkout.

Do you sell bulk orders?

Yes. Bulk ordering (5 or more vials) is available. Message us for a discounted quote & payment requirements.

GLP-3 [R] (10mg)

$55.00

Quantity

Retatrutide (codenamed LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly that represents the next major leap forward in metabolic medicine.

While first-generation drugs like Wegovy target one hormone receptor (GLP-1) and second-generation drugs like Zepbound target two (GLP-1 and GIP), Retatrutide is a "triple agonist" (or "tri-agonist"). It targets three distinct metabolic hormone pathways simultaneously, earning it the nickname "3G" or "Triple G."

The Triple-Agonist Mechanism

By stimulating three different receptors at the same time, retatrutide tackles weight loss, appetite, and energy expenditure through a multi-pronged approach:

GLP-1 (Glucagon-like peptide-1): Slows digestion, reduces appetite, and improves insulin secretion.
GIP (Glucose-dependent insulinotropic polypeptide): Acts synergistically with GLP-1 to enhance insulin secretion, reduce nausea, and improve how the body stores and breaks down fat cells.
Glucagon: This is the game-changer. While glucagon normally raises blood sugar when you are fasting, activating it therapeutically speeds up metabolism and increases calorie burning (energy expenditure). It acts as an internal furnace while the other two hormones suppress your desire to eat.

Surgical-Level Results: The Phase 3 Trial Data

Eli Lilly released groundbreaking Phase 3 data from its TRIUMPH-1 clinical trials. The results have set a massive new benchmark in obesity medicine, achieving weight loss percentages previously only possible through bariatric surgery.

TRIUMPH-1 Key Metrics (Adults with Obesity/Overweight)

Average Weight Loss: At the highest weekly dose (12 mg), participants lost an astounding average of 28.3% of their body weight (about 70 lbs) at 80 weeks.
Two-Year Results: In an extended 104-week tracking period for severe obesity, weight loss reached an average of 30.3%.
The 30% Threshold: Nearly half (45.3%) of the participants on the 12 mg dose achieved a body weight reduction of 30% or greater.
Cardiometabolic Perks: Participants experienced an average waist circumference reduction of nearly 9.5 inches ($24.1\text{ cm}$), alongside major drops in blood pressure, triglycerides, and non-HDL cholesterol.

Side Effects & Current Regulatory Status

The side effect profile is largely identical to existing drugs like Mounjaro or Ozempic, primarily consisting of gastrointestinal issues like nausea, diarrhea, vomiting, and constipation, which peak during the dose-escalation phase.

⚠️ A Unique Glucagon Signal: Because retatrutide hits the glucagon receptor, trials noted a unique side effect called dysesthesia (a mild skin sensitivity or tingling sensation) in about 12% of patients on the highest dose, though most cases resolved on their own.

When will it be available?

Retatrutide is not yet FDA-approved or legally available for prescription. Eli Lilly is finalizing its Phase 3 data submissions, with plans to formally file for FDA approval. Regulatory review typically takes 10 to 12 months, meaning commercial availability in pharmacies is anticipated around late 2027 or early 2028.

Because of the massive internet hype surrounding these 30% weight loss figures, global health authorities have strictly warned against illegal, unapproved, or compounded "black market" versions online, which are unregulated and highly unsafe.